bioAffinity Technologies, Inc.
NASDAQ: BIAFW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Maria Zannes
- Employees
- 57
- Headquarters
- San Antonio, United States
- IPO year
- 2026
- Market cap
- $3.8M
- Website
- http://www.bioaffinitytech.com
Loading BIAFW…
Loading profile data…Frequently asked questions about BIAFW
What does bioAffinity Technologies, Inc. (BIAFW) do?
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offer...
Where does BIAFW trade?
bioAffinity Technologies, Inc. (BIAFW) trades on the NASDAQ.
What sector is BIAFW in?
bioAffinity Technologies, Inc. (BIAFW) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of bioAffinity Technologies, Inc.?
Maria Zannes is the chief executive officer of bioAffinity Technologies, Inc. (BIAFW).
Where is bioAffinity Technologies, Inc. headquartered?
bioAffinity Technologies, Inc. is headquartered in United States.
Does BIAFW pay a dividend?
bioAffinity Technologies, Inc. (BIAFW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BIAFW go public?
bioAffinity Technologies, Inc. (BIAFW) completed its initial public offering in 2026.